-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the CDE official website showed that the esmolol hydrochloride and sodium chloride injection produced by Shanghai Haini Pharmaceuticals of Yangtze River Pharmaceutical Group was accepted by CDE for its imitation of 4 categories
Information, esmolol ultrashort β- adrenergic blocking effect, is the treatment of ventricular tachyarrhythmias, acute myocardial ischemia, hypertension after the ideal drug
Sales of terminal esmolol injection in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Terminal competition landscape of China's public medical institutions
According to data from Minai.
Source: Meinenet MED2.
Since the beginning of this year, Yangtze River has been approved for marketing of 19 blockbuster varieties.
Source: CDE official website, Minet.